PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15457966

[Autoimmune hepatitis].

M H Heim
View original source ↗Export metadata ↓

Abstract

Autoimmune hepatitis (AIH) is chronic, predominantly periportal hepatitis with hypergammaglobulinemia and tissue autoantibodies. It is a relative rare disorder, with a preponderance of female patients, that can present at any age. Its diagnosis relies on the exclusion of viral, metabolic, genetic and toxic etiologies of chronic hepatitis or hepatic injury. There are no pathognomonic features, but the presence of antinuclear and smooth muscle antibodies or liver-kidney microsomal antibodies together with typical histological features in liver biopsy allows the diagnosis with good confidence. Corticosteroid therapy is effective in most patients. Because of a favorable side effect profile, the combination therapy with azathioprine should be used whenever possible. Relapses after initial treatment responses are frequent, but in the majority of patients the disease can be controlled. Liver transplantation is effective, and shows good 10-year survival rates.

Explore related subjects

Anti-Inflammatory AgentsAzathioprineDiagnosis, DifferentialDrug Therapy, CombinationFemaleHepatitis, AutoimmuneHumansImmunosuppressive AgentsMalePrednisonePrognosisRandomized Controlled Trials as TopicRecurrenceRemission InductionRisk FactorsTime FactorsComparative StudyEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M H Heim. 2004. [Autoimmune hepatitis].. https://doi.org/10.1024/0040-5930.61.8.499

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup.

BACKGROUND: Although previous studies have shown that dexamethasone is useful in croup, the optimal dosage has not been clarified yet. The aim of this study was to investigate the effectiveness of dexamethasone 0.15 mg/kg single dose compared with the recommended dose of 0.6 mg/kg for treatment of hospitalized children with moderate to severe croup. METHOD: Forty-one children aged 6 months to 5 years admitted from March 2001 to October 2003 at the pediatric ward of Hatyai Hospital with moderate to severe croup were recruited for the study. After random allocation, each child received a single intravenous injection of either dexamethasone 0.6 mg/kg (maximum dose 12 mg) or 0.15 mg/kg (maximum dose 3 mg). All children were given a single dose of epinephrine nebulization at the beginning of the study. The croup scores were measured at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h after the dexamethasone injection. RESULTS: One hour following the injection, the mean croup scores were significantly reduced from baseline values in both groups (p<0.01). There was no difference in the mean croup scores between the two groups at any time. Median times to croup scores equal or less than two in both high- and low-dose groups were 8 and 7.9 h, respectively. No patient required intubation or was removed from the study because of a rising croup score after enrollment. There was no significant adverse reaction from dexamethasone treatment in either group. CONCLUSION: Dexamethasone 0.15 and 0.6 mg/kg are equally effective in the treatment of moderate to severe croup.

Anti-Inflammatory Agents↗